by Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra

Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0

Research carried out by a group from Cima and the Clínica Universidad de Navarra has described the composition of the immune system in blood samples from patients with multiple myeloma, by generating a new immunological atlas, and has revealed how changes in immune cells themselves can influence the efficacy of vaccines such as that against COVID-19.

Multiple myeloma is a type of cancer characterized by an uncontrolled growth of a subset of immune cells—plasma cells—which promote immune changes that make patients more susceptible to infections, the main cause of death.

A study developed at the Cancer Center Clínica Universidad de Navarra, and led by Dr. Esperanza Martín-Sánchez and Dr. Bruno Paiva, analyzed blood samples from 28 patients with multiple myeloma and compared them with those from 96 healthy individuals.

The results, published in Blood Cancer Journal, confirm alterations in the composition of immune cells, especially in T and B lymphocytes. The paper is titled "Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19."

In addition, when these data were compared with those of 53 patients with other tumors that affect B-lymphocyte production, the researchers observed that multiple myeloma is associated with a more severe immune suppression.

"This new atlas of the immune system in patients with multiple myeloma is fundamental to understand how this disease affects the responsiveness of the defense system," explained Dr. Esperanza Martín-Sánchez, researcher in the Hemato-Oncology Program at Cima and first author of the publication.

Scientific group from Cima and the Clínica Universidad de Navarra that carried out the research. Credit: Manuel Castells

The scientists also analyzed how the altered immune system of multiple myeloma patients responds to COVID-19 vaccination. These data complement previous results published in 2022 by the same group, which confirmed that the efficacy of the COVID-19 vaccine could be lower in patients with hematological tumors.

"Due to immunological changes, vaccine administration to these patients may not have the same efficacy as in the healthy population. It is therefore important to know how their immune system is affected in order to establish specific actions to effectively prevent the risk of infections," Dr. Martín-Sánchez points out.

Dr. Bruno Paiva, co-director of the Hemato-Oncology Program at Cima, suggests that "our findings will allow us to develop more personalized and effective programs to vaccinate and prevent infections for these patients. For instance, we will be able to find the most appropriate vaccination timing for them, which will be when their defense system is less altered and, then, more likely to generate an adequate immune response."

A less invasive method for the patient

One of the key aspects of this study is that immune composition has been depicted in blood samples. Dr. Martín-Sánchez explains that "the benefit of studying blood samples is two-fold. Firstly, they provide essential information on the patient's immune status, since they act as a mirror of the bone marrow; and, secondly, they are obtained through a minimally invasive method.

"So far, most studies have analyzed bone marrow samples, because it is where blood cells are produced and the usual niche for tumor plasma cells. However, obtaining these samples requires a bone marrow aspirate, which in many cases is painful for the patient."

The research has been developed with the participation of the Basque-Navarre Association of Hematology and Hemotherapy in collaboration with several scientific groups of the Centro de Investigación Biomédica en Red (CIBERONC).

More information: Esperanza Martín-Sánchez et al, Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19, Blood Cancer Journal (2024). DOI: 10.1038/s41408-024-01089-5

Journal information: Blood Cancer Journal 

Provided by Centro de Investigación Médica Aplicada (CIMA) Universidad de Navarra